Total Payments
$222,035
2024 Payments
$23,881
Companies
25
Transactions
162
Medicare Patients
726
Medicare Billing
$173,415
Payment Breakdown by Category
Consulting$132,382 (59.6%)
Research$41,299 (18.6%)
Travel$30,557 (13.8%)
Other$14,370 (6.5%)
Food & Beverage$3,414 (1.5%)
Education$11.92 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $132,382 | 44 | 59.6% |
| Unspecified | $41,299 | 21 | 18.6% |
| Travel and Lodging | $30,557 | 44 | 13.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,870 | 4 | 4.4% |
| Honoraria | $4,500 | 1 | 2.0% |
| Food and Beverage | $3,414 | 47 | 1.5% |
| Education | $11.92 | 1 | 0.0% |
Payments by Type
General
$180,736
141 transactions
Research
$41,299
21 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | $66,601 | 51 | $0 (2024) |
| PFIZER INC. | $53,366 | 36 | $0 (2024) |
| F. Hoffmann-La Roche AG | $28,209 | 11 | $0 (2022) |
| Janssen Global Services, LLC | $15,030 | 6 | $0 (2023) |
| Eli Lilly and Company | $14,696 | 4 | $0 (2019) |
| Takeda Pharmaceuticals U.S.A., Inc. | $10,417 | 8 | $0 (2020) |
| Amgen Inc. | $6,425 | 6 | $0 (2024) |
| Alkermes, Inc. | $5,120 | 1 | $0 (2022) |
| Genentech, Inc. | $4,465 | 6 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $3,600 | 4 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $23,881 | 10 | PFIZER INC. ($18,415) |
| 2023 | $15,434 | 11 | Janssen Global Services, LLC ($6,750) |
| 2022 | $40,083 | 16 | F. Hoffmann-La Roche AG ($17,827) |
| 2021 | $18,969 | 11 | PFIZER INC. ($9,460) |
| 2020 | $24,072 | 16 | Bayer HealthCare Pharmaceuticals Inc. ($10,499) |
| 2019 | $56,267 | 39 | Bayer HealthCare Pharmaceuticals Inc. ($31,528) |
| 2018 | $27,953 | 37 | Bayer HealthCare Pharmaceuticals Inc. ($12,423) |
| 2017 | $15,377 | 22 | Janssen Global Services, LLC ($8,280) |
All Payment Transactions
162 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Bayer Healthcare Pharmaceuticals Inc. | Vitrakvi (Drug) | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| Category: Oncology | ||||||
| 11/22/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $15,300.00 | General |
| 09/26/2024 | Bayer Healthcare Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| 09/25/2024 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $2,002.65 | General |
| 09/25/2024 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $564.19 | General |
| 09/25/2024 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $279.59 | General |
| 09/25/2024 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $268.18 | General |
| 06/27/2024 | Amgen Inc. | LUMAKRAS (Drug) | — | In-kind items and services | $900.43 | Research |
| Study: ITC soto+pani vs T/T+beva in mCRC • Category: Oncology | ||||||
| 06/02/2024 | BeiGene USA, Inc. | — | Food and Beverage | In-kind items and services | $140.76 | General |
| 05/08/2024 | Amgen Inc. | LUMAKRAS (Drug) | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| Category: Oncology | ||||||
| 11/28/2023 | Janssen Global Services, LLC | — | Consulting Fee | Cash or cash equivalent | $6,750.00 | General |
| 10/05/2023 | Bayer Healthcare Pharmaceuticals Inc. | Vitrakvi (Drug) | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| Category: Oncology | ||||||
| 09/25/2023 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $3,136.00 | General |
| 09/12/2023 | Amgen Inc. | LUMAKRAS (Drug) | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| Category: Oncology | ||||||
| 07/20/2023 | Bayer Healthcare Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $1,050.00 | General |
| 06/03/2023 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $129.26 | General |
| Category: Oncology | ||||||
| 06/03/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | In-kind items and services | $108.94 | General |
| Category: ONCOLOGY | ||||||
| 04/18/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $109.34 | General |
| Category: ONCOLOGY | ||||||
| 04/17/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| 03/20/2023 | Amgen Inc. | LUMAKRAS (Drug) | Consulting Fee | Cash or cash equivalent | $550.00 | General |
| Category: Oncology | ||||||
| 03/15/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| 12/13/2022 | Bayer HealthCare Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| 12/13/2022 | Bayer HealthCare Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $75.47 | General |
| 11/28/2022 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| 11/21/2022 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 1B TRIAL OF LY2606368 IN COMBINATION WITH CISPLATIN OR CETUXIMAB IN ADVANCED AND-OR METASTATIC TUMORS | Eli Lilly and Company | $9,853 | 1 |
| ONCOLOGY PORTFOLIO CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $7,960 | 4 |
| A PHASE 1A-1B STUDY OF A NOVEL ANTI-PD-L1 CHECKPOINT ANTIBODY -LY3300054- ADMINISTERED ALONE OR IN COMBINATION WITH OTHER AGENTS IN ADVANCED REFRACTORY SOLID TUMORS -PHASE 1A-1B ANTI-PD-L1 COMBINATIONS IN TUMORS-PACT | Eli Lilly and Company | $4,596 | 1 |
| GEDATOLISIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,980 | 2 |
| An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK123, ROS1, or ALK Gene Rearrangements | F. Hoffmann-La Roche AG | $3,326 | 2 |
| AN OPEN-LABEL, MULTICENTER, GLOBAL PHASE 2 BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOR NTRK123, ROS1, OR ALK GENE REARRANGEMENTS | F. Hoffmann-La Roche AG | $2,980 | 1 |
| STARTRK 2 RXDX 101 02 | F. Hoffmann-La Roche AG | $2,387 | 1 |
| ITC soto+pani vs T/T+beva in mCRC | Amgen Inc. | $900.43 | 1 |
| STARTRK 2 RXDX 101 02, ALKA ALKA 372 001 and STARTRK 1 RXDX 101 01 | F. Hoffmann-La Roche AG | $872.34 | 1 |
| COMPARING PHASE 3 GO DECISIONS PH3-GO BETWEEN SINGLE ARM TRIALS WITH REAL WORLD EXTERNAL CONTROL SATRWEC VS. RANDOMIZED PHASE 2 TRIALS RPH2 | F. Hoffmann-La Roche AG | $679.17 | 1 |
| A PHASE 2 MULTICENTER RANDOMIZED PARALLEL-ARM PLACEBO-CONTROLLED STUDY OF LY3074828 IN SUBJECTS WITH ACTIVE CROHNS DISEASE (SERENITY) | Eli Lilly and Company | $225.00 | 1 |
| A Phase 11b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib RXDX-101 in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors, with or without TRK, ROS1, or ALK Fusions, An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK123, ROS1, or ALK Gene Rearrangements, A Phase I Dose Escalation Study of Entrectinib RXDX-101 in Adult | F. Hoffmann-La Roche AG | $137.37 | 1 |
| Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | Seattle Genetics, Inc. | $119.22 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | Novartis Pharmaceuticals Corporation | $114.60 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 235 | 506 | $249,322 | $53,755 |
| 2022 | 4 | 211 | 442 | $200,915 | $47,750 |
| 2021 | 3 | 158 | 380 | $191,878 | $45,517 |
| 2020 | 2 | 122 | 317 | $139,149 | $26,394 |
Total Patients
726
Total Services
1,645
Medicare Billing
$173,415
Procedure Codes
15
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 161 | 401 | $214,540 | $44,988 | 21.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 20 | 20 | $14,364 | $2,926 | 20.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 39 | $8,713 | $2,454 | 28.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 20 | 21 | $5,602 | $1,652 | 29.5% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 12 | 12 | $3,900 | $1,111 | 28.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 11 | 13 | $2,203 | $624.28 | 28.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 140 | 320 | $164,529 | $37,292 | 22.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 25 | 26 | $14,572 | $4,205 | 28.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 25 | 51 | $14,433 | $4,043 | 28.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 21 | 45 | $7,381 | $2,210 | 29.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 130 | 351 | $174,213 | $41,083 | 23.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 16 | 16 | $10,776 | $2,446 | 22.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 12 | 13 | $6,889 | $1,988 | 28.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 104 | 266 | $127,167 | $23,037 | 18.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 18 | 51 | $11,982 | $3,356 | 28.0% |
About Dr. David Hong, M.D
Dr. David Hong, M.D is a Medical Oncology healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1255439469.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Hong, M.D has received a total of $222,035 in payments from pharmaceutical and medical device companies, with $23,881 received in 2024. These payments were reported across 162 transactions from 25 companies. The most common payment nature is "Consulting Fee" ($132,382).
As a Medicare-enrolled provider, Hong has provided services to 726 Medicare beneficiaries, totaling 1,645 services with total Medicare billing of $173,415. Data is available for 4 years (2020–2023), covering 15 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Houston, TX
- Active Since 09/20/2006
- Last Updated 03/04/2011
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1255439469
Products in Payments
- Vitrakvi (Drug) $42,728
- Non-Covered $17,323
- ROZLYTREK (Biological) $6,722
- LUMAKRAS (Drug) $3,650
- IMFINZI (Drug) $897.11
- KRAZATI (Drug) $218.28
- BRUKINSA (Drug) $129.26
- LAG525 (Drug) $114.60
- Abraxane (Drug) $114.10
- VERZENIO (Drug) $60.34
- Other (Device) $15.03
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Houston
Roy Herbst, M.d., Phd, M.D., PHD
Medical Oncology — Payments: $1.6M
Medical Oncology $1.6M
Dr. Putao Cen, Md, MD
Medical Oncology — Payments: $817,580
Medical Oncology $817,580
Hagop Kantarjian, Md, MD
Medical Oncology — Payments: $740,835
Medical Oncology $740,835
Dr. Matthew Ellis, Md Phd, MD PHD
Medical Oncology — Payments: $714,994
Medical Oncology $714,994
Eleni Efstathiou, M.d, M.D
Medical Oncology — Payments: $600,908
Medical Oncology $600,908
Srdan Verstovsek, M.d., Phd, M.D., PHD
Medical Oncology — Payments: $577,763
Medical Oncology $577,763